{ "items": [ "\n\n
\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n27 November 2020
\n \n \n \nIn Covid-19, inhaled budesonide may prevent damaging inflammation, stop the virus from getting into lung cells and inhibit viral replication.
\n \n\n \n \n\n \n\n \n \n \n \n Awards and Appointments\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n24 November 2020
\n \n \n \nThe University of Oxford team who have developed a COVID-19 vaccine in record time have been shortlisted for the Excellence in Healthcare Award at the NHS Parliamentary Awards.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n23 November 2020
\n \n \n \nThe University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n20 November 2020
\n \n \n \nPreventing serious complications from COVID-19 in potentially vulnerable populations in high risk environments, such as prisons, and preventing spread to surrounding communities needs a coordinated evidence-based approach to managing outbreaks of COVID-19 in prison settings.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n20 November 2020
\n \n \n \nA new study suggests that individuals who have previously had COVID-19 are highly unlikely to contract the illness again, for at least six months following their first infection.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n20 November 2020
\n \n \n \nNew research into the HIV-1 virus has shed light on an important factor in the evolution of viruses, which is likely also to affect SARS-CoV-2 (the virus which causes COVID-19). This new insight could have important implications for vaccine development.
\n \n\n \n \n\n \n\n \n \n \n \n Clinical Trials\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n19 November 2020
\n \n \n \nThe ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n17 November 2020
\n \n \n \nMental health difficulties in children increased during the first national lockdown (between March and June 2020), but have decreased since.
\n \n\n \n \n\n \n\n \n \n \n \n Clinical Trials\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n16 November 2020
\n \n \n \nA trial of a new inhaled antiviral drug for COVID-19 has shown positive results and the drug is now moving into a larger international phase 3 trial of hospitalised patients.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n12 November 2020
\n \n \n \nThe University of Oxford has secured a critical professorship in vaccinology for the future following a gift of \u00a33.33 million from the Sa\u00efd family. The gift will enable Professor Sarah Gilbert, the inaugural post holder, to continue her ground-breaking research in the field, while also helping to ensure that Oxford remains at the forefront of vaccine development for generations to come.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n12 November 2020
\n \n \n \nExtensive clinical evaluation from Public Health England and the University of Oxford show Lateral Flow Tests are accurate and sensitive enough to be used in the community, including for asymptomatic people.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n10 November 2020
\n \n \n \nThe University of Oxford has joined forces with Thermo Fisher Scientific, the world leader in serving science, to ramp up the university\u2019s capacity to deliver COVID-19 testing data.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n10 November 2020
\n \n \n \nNew study suggests that having COVID-19 increases a person\u2019s risk of developing psychiatric disorders, and that having a psychiatric disorder increases the chance of getting COVID-19. The study, published in The Lancet Psychiatry, used the TriNetX electronic health records of 69 million people in the USA including over 62,000 cases of COVID-19.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n9 November 2020
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n9 November 2020
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n6 November 2020
\n \n \n \nAntibodies to COVID-19 fall by half in less than 90 days, and antibody levels peak lower and fall faster in younger adults, an ongoing study of staff at Oxford University Hospitals NHS Foundation Trust has revealed.
\n \n\n \n \n\n \n\n \n \n \n \n Clinical Trials\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n2 November 2020
\n \n \n \nKenya has joined the global efforts in search of an effective vaccine for COVID-19 with the start of a trial evaluating the ChAdOx1 nCoV-2019 Oxford coronavirus vaccine.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n30 October 2020
\n \n \n \nThe University of Oxford will take part in a new pilot scheme to assess the use of Lateral Flow Tests (LFTs), a new COVID-19 test designed to identify asymptomatic individuals with the virus.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n Innovation\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n29 October 2020
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n29 October 2020
\n \n \n \nMore than 6,000 patients who underwent endoscopy at 18 NHS hospitals since the start of pandemic have been tested and none contracted COVID as a result of the procedure, a study involving clinicians from Oxford University Hospitals (OUH) NHS Foundation Trust has found.
\n \n\n \n \n